Q&A with Genentech CEO Alexander Hardy on Medicare’s drug price negotiations

Before and after it was acquired by Roche, Genentech has made a name for itself with biologics — the large molecules that Congress recently afforded 13 years of protection before new price negotiations can kick in from Medicare.

The expanse of those negotiations, and how they’re about to be implemented,…